These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: ABT-387/r early access program expanded further.
    Journal: Res Initiat Treat Action; 1999 Dec; 5(5):22. PubMed ID: 11366887.
    Abstract:
    In November, Abbott Laboratories expanded its early access program criteria for ABT-378/r in the United States. Patients who have up to 200 CD4 T cells and who have failed numerous antiretroviral regimens are now eligible for the program. In February 2000, the program will be expanded further. At that time, patients who have no viable therapy with any of the approved antiretrovirals may have access to ABT-378/r regardless of their viral loads, CD4 T cell counts, or history of protease inhibitor use. Contact information is provided.
    [Abstract] [Full Text] [Related] [New Search]